New data from ASCO 2026 highlights a significant clinical achievement for immunotherapy-resistant lung cancer: BioNTech and Pfizer’s BNT327 bispecific antibody achieved disease control in 67% of heavily pretreated patients who had previously failed multiple standard therapies. This overall response rate masks important variations across patient populations. Second-line patients achieved the highest disease control rate at 78%, while third-line patients reached 67%, and fourth-line or beyond patients achieved 52%—demonstrating sustained activity even in the most refractory cases. Most strikingly, the therapy showed clinical benefit in patients who had already progressed on prior PD-1 inhibitors, a population typically considered difficult to treat. This finding suggests that the bispecific approach’s simultaneous targeting of PD-L1 and VEGF-A pathways can effectively overcome resistance mechanisms that limit single-agent immunotherapy efficacy. These Phase I results support continued development toward larger confirmatory trials. Read the full article on GMJ Newsroom.
Was this article helpful?
